当前位置: 首页 >> 检索结果
521. The Value of Ultrasound in Patients with T1-T2 Breast Cancer with No Palpable Lymph Nodes Enrolled in the EORTC 10981-22023 AMAROS Trial.
作者: A W J Beerthuizen.;T I M Snellen.;S A Bartels.;A Kuijer.;C Poncet.;C A Drukker.;E J T Rutgers.;M J T F D Vrancken Peeters.;F H van Duijnhoven.
来源: Ann Surg Oncol. 2026年33卷4期3293-3301页
The use of axillary ultrasound (AUS) in breast cancer staging varies across international guidelines, ranging from routine use to targeted implementation. This study evaluates the clinical utility of AUS in patients enrolled in the AMAROS trial.
522. Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.
作者: Sidsel Pedersen.;Mikkel Byrdal.;Evelina Martinenaite.;Cathrine Lund Lorentzen.;Julie Westerlin Kjeldsen.;Steffen Ullitz Thorsen.;Anders Kverneland.;Mai-Britt Zocca.;Mads Hald Andersen.;Inge Marie Svane.
来源: Nat Commun. 2025年17卷1期806页
We report long-term clinical and immunologic outcomes from the MM1636 trial (NCT03047928), which evaluated a peptide vaccine targeting IDO and PD-L1 in combination with nivolumab in patients with advanced melanoma. At a five-year follow-up, the combination demonstrated durable clinical efficacy, with a 25.5-month median progression-free survival. Serum proteomic profiling identified vaccine-specific immune signatures, with increase in CCL3, CCL4, and TNFα emerging as biomarkers of long progression-free survival. Increase in these markers were not observed in a matched anti-PD-1 monotherapy cohort, suggesting distinct immune modulation by the vaccine. Functional studies confirmed vaccine-induced targeting of myeloid cells and associated increase in these cytokines. These findings provide evidence for durable benefit from immune modulatory vaccination and nominate CCL3, CCL4, and TNFα as candidate biomarkers for response.
523. Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.
作者: K L Jhaveri.;P Neven.;M L Casalnuovo.;S-B Kim.;E Tokunaga.;P Aftimos.;C Saura.;J O'Shaughnessy.;N Harbeck.;L A Carey.;G Curigliano.;J Watanabe.;E Lim.;J Huang.;Z Qingyuan.;A Llombart-Cussac.;C Huang.;B Desai.;Y Limay.;X A Wang.;S Cao.;F C Bidard.
来源: Ann Oncol. 2026年37卷4期532-543页
At the primary progression-free survival (PFS) analysis, the phase III EMBER-3 trial in endocrine therapy-pretreated patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) demonstrated significant PFS benefit with imlunestrant versus standard of care (SOC: fulvestrant or exemestane) in patients with ESR1 mutations (ESR1m) and with imlunestrant-abemaciclib versus imlunestrant in all patients, regardless of ESR1m. In this article, we report updated efficacy from a prespecified interim overall survival (OS) analysis.
524. Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
作者: Steven J Frank.;Paul M Busse.;J Jack Lee.;David I Rosenthal.;Mike Hernandez.;David M Swanson.;Adam S Garden.;G Brandon Gunn.;Samir H Patel.;James W Snider.;Daniel J Ma.;Jason K Molitoris.;Nancy Y Lee.;Upendra Parvathaneni.;Mark W McDonald.;Noah S Kalman.;Alexander Lin.;Nasiruddin Mohammed.;Christina Henson.;Christian Hyde.;Gopal K Bajaj.;Sanford R Katz.;Roi Dagan.;William H Morrison.;Jay P Reddy.;C David Fuller.;Shalin J Shah.;Jack Phan.;Gregory M Chronowski.;Lauren Mayo.;Erich M Sturgis.;Renata Ferrarotto.;Xiaorong R Zhu.;Xiaodong Zhang.;Li Wang.;Katherine A Hutcheson.;Adel K El-Naggar.;Amy C Moreno.;Anna Lee.;Michael T Spiotto.;Neil D Gross.;Stephen Y Lai.;Jay J Liao.;Jonathan Paly.;Zhongxing Liao.;Robert L Foote.; .
来源: Lancet. 2026年407卷10524期174-184页
Radiotherapy is an integral component of treatment for oropharyngeal cancer. Toxicity from the current state-of-the-art photon radiotherapy, intensity-modulated radiation therapy (IMRT), has prompted the search for alternative, less toxic therapies. One such alternative that might de-intensify treatment is proton therapy. In this trial, we aimed to directly compare IMRT with intensity-modulated proton therapy (IMPT), both concurrent with systemic therapy, hypothesising comparable disease control and survival and lower toxicity.
525. Three-dimensional visualization helps surgoens to make surgical decision: The 3D-ViDru trial - a randomized trial.
作者: Esther Giehl-Brown.;Frederic Konrad.;Steffen Löck.;Johannes Schweipert.;Felix Schön.;Jens-Peter Kühn.;Jürgen Weitz.;Carina Riediger.
来源: Hepatobiliary Pancreat Dis Int. 2026年25卷1期52-61页
Successful liver resection in oncologic surgery depends on safety, precision, and efficacy, all of which require a thorough understanding of liver anatomy. Contrast-enhanced computed tomography (CT)-generated three-dimensional (3D) models have been proposed as a valuable tool to enhance this understanding. However, a systematic comparison of different display modalities across professional groups has not yet been performed.
526. Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study.
作者: Rosie Maye Solomon.;Robert D Morgan.;Laura Horsley.;Kalena Marti-Marti.;Danielle Shaw.;Andrew R Clamp.;Mark P Saunders.;Saifee Mullamitha.;Jurjees Hasan.;Prakash Manoharan.;James P B O'Connor.;Caroline Dive.;Michael Braun.;Cong Zhou.;Gordon C Jayson.
来源: Clin Colorectal Cancer. 2026年25卷1期115-124页
The TRAVASTIN study dentified plasma Tie2 as the first vascular response biomarker for bevacizumab in metastatic colorectal cancer. Tie2-defined vascular responders had significantly longer progression-free survival (PFS) compared to nonresponders. Here, we report overall survival (OS) in TRAVASTIN after 7.7 years of follow-up, explore efficacy of bevacizumab use and reuse, and assess plasma Tie2 performance as a response biomarker.
527. Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PC.
作者: Astrid E Persson.;Elisabeth Kjellén.;Hans Garmo.;Gabriel Adrian.;Pär Stattin.;Anders Widmark.;Per Nilsson.;Adalsteinn Gunnlaugsson.
来源: Radiother Oncol. 2026年215卷111323页
HYPO-RT-PC was the first phase 3 trial showing the long-term efficacy and safety of extremely hypofractionated radiotherapy schedules (ultra-hypofractionation or stereotactic body radiotherapy) compared with standard radiotherapy in localised prostate cancer. We aimed to verify their safety in the context of a clinical trial, by comparing events of potentially radiotherapy-related morbidity according to routinely collected health data between the arms and with men unexposed to prostate radiotherapy.
528. Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung).
作者: Kristof Cuppens.;Marcel Wiesweg.;Paul Baas.;Brigitte Maes.;Bert Du Pont.;Till Ploenes.;Dirk Theegarten.;Michel Vanbockrijck.;Clemens Aigner.;Koen Hartemink.;Fabian Doerr.;Servet Bölükbas.;Karin Pat.;Martin Schuler.
来源: Eur J Cancer. 2026年233卷116165页
Preoperative immunotherapy targeting PD-1/-L1 with chemotherapy induces histopathological responses and improves survival in patients with resectable non-small cell lung cancer (NSCLC). NEOpredict-Lung (NCT04205552) established the feasibility of dual blockade of PD-1 and LAG-3 immune checkpoints prior to curatively intended resection. Here we report extended follow-up, postoperative treatments and patterns of response and recurrence.
529. Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion.
作者: Sarina A Piha-Paul.;Chieh Tseng.;Emily Thompson.;R Jason Stafford.;Hung Le.;Lei Kang.;Siqing Fu.;Apostolia Tsimberidou.;George Blumenschein.;Jordi Rodon Ahnert.;John M Slopis.;David Hong.;Aung Naing.;Funda Meric-Bernstam.;Chaan S Ng.;Shannon Westin.;Anil K Sood.
来源: Oncologist. 2026年31卷3期
Bevacizumab and temsirolimus target angiogenic and mTOR pathways in cancer progression.
530. Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial.
作者: Wenfeng Fang.;Jian Fang.;Panwen Tian.;Yun Fan.;Qitao Yu.;Xiaochun Zhang.;Zhehai Wang.;Xiaoyuan Liu.;Yanjun Shi.;Li Zhang.
来源: Cancer Med. 2025年14卷24期e71469页
Few treatment options are available for patients with epidermal growth factor receptor (EGFR) mutation-positive metastatic non-squamous non-small cell lung cancer (NSCLC) who failed treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs). We aimed to assess the efficacy and safety of atezolizumab plus bevacizumab in these patients.
531. Diagnostic Accuracy of [18F]FDG PET/CT versus CT for NSCLC Surveillance: Secondary Analysis of a Randomized Clinical Trial.
作者: Kasper Foged Guldbrandsen.;Martin Bloch.;Kristin Skougaard.;Elisabeth Albrecht-Beste.;Hanne Marie Nellemann.;Martin Krakauer.;Peter Michael Gørtz.;Julie Marie Grüner.;Joan Fledelius.;Anne Lerberg Nielsen.;Paw Christian Holdgaard.;Søren Steen Nielsen.;Karin Hjorthaug.;Lise Barlebo Ahlborn.;Erik Jakobsen.;Anette Højsgaard.;Rene Horsleben Petersen.;Lars Borgbjerg Møller.;Morten Dahl.;Boe Sandahl Sorensen.;Malene Støchkel Frank.;Jeanette Haar Ehlers.;Zaigham Saghir.;Mette Pøhl.;Svetlana Borissova.;Lotte Holm Land.;Charlotte Kristiansen.;Tine McCulloch.;Lise Saksø Mortensen.;Malene Søby Christophersen.;Ole Hilberg.;Thor Lind Rasmussen.;Signe Høyer Simonsen Schwaner.;Christian B Laursen.;Uffe Bodtger.;Markus Nowak Lonsdale.;Christian Niels Meyer.;Oke Gerke.;Jann Mortensen.;Torben Riis Rasmussen.;Barbara Malene Fischer.; .
来源: Clin Lung Cancer. 2026年27卷3期180-189.e1页
Following curative treatment for non-small cell lung cancer (NSCLC), surveillance to detect recurrence is recommended. While computed tomography (CT) is the current standard for follow-up imaging, the optimal surveillance strategy remains debated. This study compares the diagnostic accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT; hereafter referred to as PET/CT) and CT for NSCLC surveillance.
532. Cost Effectiveness of Local Anaesthetic Transperineal Versus Transrectal Biopsy: Results from the TRANSLATE Study.
作者: Matthew Little.;Jane Wolstenholme.;Filipa Landeiro.;Ioana R Marian.;Roxanne Williams.;J Francisco Lopez.;Claudia Mercader.;Mutie Raslan.;Christopher Berridge.;Jessica Whitburn.;Teresa Campbell.;Steve Tuck.;Vicki S Barber.;Jessica Scaife.;Aimi Hewitt.;Amy Taylor.;Alexander Ooms.;Sukanya Ghosh.;John M Reynard.;Freddie C Hamdy.;Matthew P C Liew.;Tom Leslie.;James W F Catto.;Derek J Rosario.;Altan Omer.;Daniel W Good.;Rob Gray.;Sashi Kommu.;Daniel Chung.;Hannah Wells.;Krishna Narahari.;Ruth E Macpherson.;Clare Verrill.;Ben Eddy.;Hide Yamamoto.;Richard J Bryant.;Alastair D Lamb.; .
来源: Eur Urol Focus. 2026年12卷2期227-236页
A local anaesthetic ultrasound-guided transperineal (LATP) prostate biopsy has advantages over transrectal ultrasound (TRUS)-guided biopsy, with improved magnetic resonance imaging (MRI)-guided prostate cancer detection and lower rates of infection-related complications. However, uncertainty remains regarding the cost effectiveness of an LATP biopsy compared with a TRUS biopsy.
533. E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study.
作者: S Kondo.;N Yamamoto.;Y Katsuya.;J Sato.;S Mishima.;A Kawazoe.;E Oki.;K Yamazaki.;S Itoh.;T Yokota.;S Nagao.;T Kimura.;S Yamamuro.;N Hayata.;T Tamai.;K Shitara.
来源: ESMO Open. 2025年10卷12期105893页
E7386 is an orally active inhibitor reported to block the CBP/β-catenin interaction. We present data from the dose-escalation and expansion part 1 of Study 103 (phase I) of E7386 in patients with advanced, unresectable, or recurrent (A/U/R) solid tumors.
534. Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).
作者: Brian M Slomovitz.;S John Weroha.;Wei Deng.;Hye Sook Chon.;Vivek Podder.;Mary Tilley Jenkins Vogel.;Floor Backes.;Eric D Thomas.;Lee-May Chen.;Meaghan Elizabeth Tenney.;Shannon N Westin.;Merry Jennifer Markham.;David S Miller.;Mitchell I Edelson.;Carolyn Y Muller.;Michael J Callahan.;Laura L Holman.;J Rebecca Liu.;Eleonora Teplinsky.;Aparna Kamat.;Michael Guy.;Jing-Yi Chern.;Jayanthi Lea.;Martina Murphy.;Grace M Choong.;Elena D Moore.;Edwin A Alvarez.;William H Rodgers.;David M O'Malley.;Larry J Copeland.;Thomas J Herzog.;Robert L Coleman.;David M Gershenson.
来源: J Clin Oncol. 2026年44卷3期153-163页
Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6)-p16-Rb pathway, features shared with hormone receptor-positive breast cancer, dual endocrine, and CDK4/6 inhibition is a biologically rational strategy. This phase II trial evaluated ribociclib plus letrozole in recurrent LGSOC.
535. Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.
作者: Juliet C Gray.;Rebekah Weston.;Cormac Owens.;Adela Canete.;Marion Gambart.;Bram De Wilde.;Karsten Nysom.;Natasha van Eijkelenburg.;Ruth Ladenstein.;Aurora Castellano.;Nicolas U Gerber.;Lynley V Marshall.;Giuseppe Barone.;Alba Rubio-San-Simon.;Antony Ng.;Sucheta Vaidya.;Soledad Gallego.;Guy Makin.;G A Amos Burke.;Anthony McCarthy.;Dermot Murphy.;C Michel Zwaan.;Ricardo López-Almaraz.;Sarah Jannier.;Estelle Thebaud.;Nadege Corradini.;Dan Yeomanson.;Lisa Howell.;Deborah A Tweddle.;Martin Elliott.;Dave Hobin.;Dominique Valteau-Couanet.;Gudrun Schleiermacher.;Pascal Chastagner.;Anne Sophie Defachelles.;Benedicte Brichard.;Sally George.;Louis Chesler.;Jennifer Laidler.;Charlotte Firth.;Grace Holt.;Veronica Moroz.;Andrew D J Pearson.;Simon Gates.;Keith Wheatley.;Pam Kearns.;Lucas Moreno.
来源: J Clin Oncol. 2026年44卷3期176-187页
Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HR-NBL) remain dismal. Here, we investigate addition of the anti-GD2 monoclonal antibody, dinutuximab beta (dB), to temozolomide (T)-based chemotherapy.
536. Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.
作者: Miguel Martín.;Ángel L Guerrero-Zotano.;María E Pérez-López.;Manuel Ruiz-Borrego.;Noelia Martínez Jáñez.;José I Chacón.;Miguel Gil-Gil.;Raquel Andrés.;Begoña Bermejo.;Pedro Sánchez-Rovira.;Sonia Del Barco.;José J Ponce.;Isaura Fernández.;Eduardo Martínez de Dueñas.;Carmen Hinojo-González.;Marta González.;Elisa García-Garre.;Blanca Hernando.;Juan de la Haba-Rodriguez.;Isabel M Álvarez.;Santiago González-Santiago.;José Á García-Sáenz.;Ana Santaballa.;Maribel Casas.;Susana Bezares.;Rosalía Caballero.;Federico Rojo.;Emilio Alba.
来源: Clin Cancer Res. 2026年32卷5期850-858页
Neoadjuvant chemotherapy is standard for high-risk hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. This study evaluates whether 12 months of letrozole plus abemaciclib could be an alternative.
537. FDG-PET-Based Selective Deescalation of Chemoradiation in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial.
作者: Michelle Mierzwa.;Benjamin Rosen.;Krithika Suresh.;Arjun Dinesh.;Sam Regan.;Collin Brummel.;Kakit Wong.;Keith Casper.;Mark Prince.;Kelly Malloy.;Andrew Shuman.;Steven Chinn.;Yue Cao.;Madhava Aryal.;Molly Heft-Neal.;Chaz Stucken.;Marisa Buchakjian.;David Forner.;Pratyusha Yalamanchi.;Paul Swiecicki.;Theodore S Lawrence.;Rawan Akhdar.;Muneesh Tewari.;Chandan Bhambhani.;Heather Walline.;J Chad Brenner.;Jennifer Shah.;Francis Worden.
来源: Clin Cancer Res. 2026年32卷4期684-693页
We conducted a phase II multicenter clinical trial to test the hypothesis that 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)-based chemoradiation (CRT) dose deescalation would provide noninferior locoregional control compared with historical controls among patients with early-stage p16+ oropharyngeal cancer. We also hypothesized that human papillomavirus (HPV) circulating tumor DNA (ctDNA) changes during treatment predict locoregional recurrence (LRR).
538. Healthcare Utilization, Costs, and Cost-Effectiveness of Patients Undergoing Laparoscopic and Open Hemihepatectomy: A Secondary Analysis of the ORANGE II PLUS Randomized Controlled, Phase 3, Superiority Trial.
作者: Bram Olij.;Gabriela Pilz da Cunha.;Merel Kimman.;Francesca Ratti.;Mohammad Abu Hilal.;Roberto I Troisi.;Robert P Sutcliffe.;Marc G Besselink.;Somaiah Aroori.;Krishna V Menon.;Bjørn Edwin.;Mathieu D'Hondt.;Valerio Lucidi.;Tom F Ulmer.;Rafael Díaz-Nieto.;Zahir Soonawalla.;Steve White.;Gregory Sergeant.;Mariëlle M E Coolsen.;Christoph Kuemmerli.;Vincenzo Scuderi.;Frederik Berrevoet.;Aude Vanlander.;Ravi Marudanayagam.;Pieter J Tanis.;Maxime J L Dewulf.;Robert S Fichtinger.;Zina B Eminton.;Ulf P Neumann.;Lloyd Brandts.;Siân A Pugh.;Åsmund A Fretland.;John N Primrose.;Ronald M van Dam.; .
来源: Ann Surg Oncol. 2026年33卷4期2882-2898页
Laparoscopic hemihepatectomy (LH) has favorable short-term outcomes compared with open hemihepatectomy (OH), including shorter hospital stay. An in-depth healthcare utilization and cost-effectiveness analysis of the international multicenter ORANGE II PLUS randomized controlled trial comparing LH and OH was performed.
539. Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats.
作者: Xue-Feng Long.;Yu-Qing Fang.;Yan-Hui Li.;Jing-Yi Li.;Xiu-Ping Wang.;Xiao-Li Wang.;Ling Zhang.;Yi Liu.
来源: Front Endocrinol (Lausanne). 2025年16卷1599879页
Metformin and liraglutide have been gradually used in the treatment of polycystic ovary syndrome (PCOS) due to their metabolic benefits, but also with some adverse reactions. Evidence suggests that gut microbiota imbalance plays an important role in the pathogenesis of PCOS. This study comprised a clinical trial to evaluate the efficacy of metformin, liraglutide, and their combination in PCOS women, and a parallel animal experiment to explore the potential involvement of gut microbiota.
540. Sorafenib plus selective internal radiotherapy with 90Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial.
作者: Grégoire Berthod.;Christophe Cisarovsky.;Tatiana Petrova.;Laurent A Decosterd.;Eva Choong.;Dan Celestini.;Michel A Cuendet.;Sarah Boughdad.;John O Prior.;Jean-Yves Meuwly.;William D Figg.;Olivier Michielin.;Serge Leyvraz.
来源: Br J Cancer. 2026年134卷4期589-597页
Selective internal radiation therapy (SIRT) and sorafenib are used for patients with liver metastases from uveal melanoma. We conducted a phase I study to determine the optimal timing of administration of sorafenib in combination with radioembolisation.
|